EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Liver Transplantation for Unresectable Colorectal Liver Metastases: Evidence, Patient Selection, and Clinical Implementation

Tor Magnus Smedman, Åsmund Avdem Fretland, Svein Dueland, Jon Solheim, Morten Hagness, Kristoffer Lassen, Pål Dag Line iD, Sheraz Yaqub iD

Cancers · 17.07.2026 · 18 (14) · 2306

DOI: 10.3390/cancers18142306 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 17.07.2026. Verfasst von Tor Magnus Smedman und 7 weiteren Autor:innen. Beteiligte Einrichtung: Transplant Oncology Research Group, Division of Surgery and Specialized Medicine, Oslo University Hospital, 0424 Oslo, Norway. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Southern and Eastern Norway Regional Health Authority, South-Eastern Norway Regional Health Authority.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver transplantation (LT) has re-emerged as a potentially curative treatment for carefully selected patients with unresectable, liver-only colorectal liver metastases (CRLM). Prospective trials (SECA-I/II) demonstrated 5-year overall survival (OS) rates of 60–83% in selected patients, findings recently corroborated by the randomized TransMet trial, which showed superior 5-year OS with LT compared with chemotherapy alone. Favorable outcomes depend on rigorous patient selection integrating clinical risk stratification (Oslo Score), tumor burden assessed by metabolic tumor volume on FDG-PET-CT, and molecular profiling, while excluding high-risk features such as BRAF V600E and RAS/TP53 co-mutations. Broader implementation raises ethical challenges related to organ allocation, driving interest in alternative strategies including living-donor LT and innovative procedures such as RAPID. This narrative review summarizes evolving evidence supporting LT for CRLM, current approaches to patient selection, oncological outcomes, and practical considerations for implementing LT into contemporary HPB and transplant practice.

Schlagwörter

Stichwörter der Autor:innen

colorectal cancer liver metastasesliver surgeryliver transplantationtransplant oncology

Autor:innen und Institutionen

  • Transplant Oncology Research Group, Division of Surgery and Specialized Medicine, Oslo University Hospital, 0424 Oslo, Norway.
  • Department of Oncology, Oslo University Hospital, 0424 Oslo, Norway.
  • Department of HBP Surgery, Oslo University Hospital, 0424 Oslo, Norway.
  • The Intervention Centre, Oslo University Hospital, 0424 Oslo, Norway.
  • Department of Transplantation Medicine, Oslo University Hospital, 0424 Oslo, Norway.
  • Institute of Clinical Medicine, University of Oslo, 0318 Oslo, Norway.

ORCID-Profile: Pål Dag Line, Sheraz Yaqub

Förderung

  • Southern and Eastern Norway Regional Health Authority
  • South-Eastern Norway Regional Health Authority

Zitieren

APA

Smedman, T. M., Fretland, Å. A., Dueland, S., Solheim, J., Hagness, M., Lassen, K., Line, P. D., & Yaqub, S. (2026). Liver Transplantation for Unresectable Colorectal Liver Metastases: Evidence, Patient Selection, and Clinical Implementation. Cancers, 18(14), 2306. https://doi.org/10.3390/cancers18142306

Vancouver

Smedman TM, Fretland ÅA, Dueland S, Solheim J, Hagness M, Lassen K, et al. Liver Transplantation for Unresectable Colorectal Liver Metastases: Evidence, Patient Selection, and Clinical Implementation. Cancers. 2026;18(14):2306. doi:10.3390/cancers18142306

BibTeX
@article{Smedman2026,
  author = {Smedman, Tor Magnus and Fretland, Åsmund Avdem and Dueland, Svein and Solheim, Jon and Hagness, Morten and Lassen, Kristoffer and Line, Pål Dag and Yaqub, Sheraz},
  title = {Liver Transplantation for Unresectable Colorectal Liver Metastases: Evidence, Patient Selection, and Clinical Implementation},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {14},
  pages = {2306},
  doi = {10.3390/cancers18142306}
}
Kostenlos starten →